Table 3.
Characteristics of the second primary malignancy cohort.
| Characteristics | SPM Cohort (n = 40) |
|---|---|
| No. (%) | |
| Site | |
| Gynecological tumors | 7 (17.5) |
| Colorectal | 6 (15.0) |
| Gastrointestinal stromal tumor | 6 (15.0) |
| Breast | 4 (10.0) |
| Thyroid | 4 (10.0) |
| Endocrine system | 4 (10.0) |
| Lung | 2 (5.0) |
| Liver | 2 (5.0) |
| Esophagus | 1 (2.5) |
| Stomach | 1 (2.5) |
| Prostate | 1 (2.5) |
| Testis | 1 (2.5) |
| Breast + lung | 1 (2.5) |
| Timing | |
| Synchronous | 17 (42.5) |
| Metachronous Antecedent |
10 (25.0) 13 (32.5) |
| Previous therapy for PanNETs in metachronous SPM | n = 10 |
| SSAs | 2 (20.0) |
| CAPTEM | 1 (10.0) |
| No | 7 (70.0) |
| Therapy for antecedent SPM administered before PanNETs occurrence | n = 13 |
| Chemotherapy | 5 (38.5) |
| Chemotherapy + Targeted therapy | 2 (15.4) |
| No | 6 (46.1) |
SPM: second primary malignancy; PanNETs: pancreatic neuroendocrine tumors; SSAs: somatostatin analogs; CAPTEM: capecitabine and temozolomide.